PhRMA retweeted
Building on our $30 billion commitment to US innovation, R&D and manufacturing, today we are celebrating the development of our Upper Merion Flex Factory. By expanding our presence in Pennsylvania, this factory will deliver best-in-class new medicines for respiratory disease and cancer.
@GovernorShapiro @PAChamber @TradeGov @montco_pa @ChamberPHL @SelectUSA
PhRMA retweeted
A strong scientific workforce is critical for America's leadership in biomedical innovation.
That's why biopharmaceutical companies have pledged +$16M to support a historic @PhRMAfoundation effort to invest in 500 early-career researchers over 3 years.
phrmafoundation.org/news-eve…
PhRMA retweeted
Great few days in London joining Bank of America and McDermott Will & Schulte for conversations about the future of biopharma. From China and AI to global competition for R&D and manufacturing, one thing is clear: U.S. leadership in medical innovation isn’t guaranteed.
We should meet that competition by making America the best place in the world to research, develop and manufacture the next generation of medicines.
PhRMA retweeted
In an exclusive interview with The Hill, Elizabeth Carpenter, EVP – Policy & Research at @PhRMA, discusses the importance of removing policy roadblocks when developing new medication:
"Incentives matter. We want companies to take those risks. There are people waiting for cures, and we know that medicine can help reduce costs elsewhere in the healthcare system."
#HillNationSummit
PhRMA retweeted
In an exclusive interview with The Hill, Robert Zirkelbach, Chief Public Affairs Officer at @PhRMA, on how the U.S. can continue its worldwide dominance in medical science:
"We need a national strategy to ensure that America is the most attractive place in the world to invest, do research, and bring medicines to patients." 🧪🧑🔬
#HillNationSummit
PhRMA retweeted
Patients like Fred rely on medicines prescribed by their doctors to treat their conditions, but finding ways to afford this medicine can often feel overwhelming, with no clear place to start. America’s Medicines can be that first step for patients to explore options – and it’s free and confidential.
Share this and help Fred spread the word!
PhRMA retweeted
Dolores is one of thousands of individuals who have been cured of Hepatitis C.
This Hepatitis Awareness Month, we recognize the impact of medical innovation and the importance of continued research to support the development of future treatments and cures.
PhRMA retweeted
There are several “distortions in our marketplace that need to be addressed to lower costs for consumers,” @PhRMA CEO @SteveUbl told @mayagoldman_ at #AxiosFOH.
“We have to get countries outside the U.S. to pay their fair share … we have to get after inefficiencies in our own system.”
PhRMA retweeted
Our new 50-state poll of 20,000+ Americans shows broad frustration with hospital markups and drug middlemen. Nearly 9 in 10 are concerned about hospital price markups, and 80% support PBM reforms that pass savings directly to patients. It's clear: Voters want action on #PBMs and #340B abuses. Read more about the survey results here: phrma.org/blog/50-state-poll…
PhRMA retweeted
Yesterday, I testified at the Energy & Commerce hearing. My thoughts on the experience here: linkedin.com/posts/lorireill…
PhRMA retweeted
Today, the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs. fda.gov/news-events/press-an…
PhRMA retweeted
I am thrilled to announce our first #WorkingforCures champion, Emily Mason, from @AstellasUS. Emily develops and implements programs that break down barriers to medication access for patients across diverse communities. Thank you, Emily, and congratulations.
PhRMA retweeted
This #DiabetesAwarenessMonth, I’m reflecting on how far science has come — and why progress only matters if every patient can access it.
Insulin is more affordable than ever, but too many families still face barriers. It’s time to fix what stands between patients and progress.
PhRMA retweeted
Momentum is building to fix the 340B hospital markup program.
The @USCBO confirmed it’s driving up federal spending and failing patients, and the Senate HELP hearing made clear the need for oversight and transparency.
Read more about the path forward ↓
linkedin.com/pulse/hidden-ta…
PhRMA retweeted
Want lower drug prices? So does Big Pharma.
Read more from @steveubl, president of @PhRMA: wapo.st/48DXk4X
PhRMA retweeted
Yesterday, we recognized our 2024 #WorkingForCures champions and celebrated their accomplishments. Congratulations and thank you again for your tireless dedication to our industry. workingforcures.org
PhRMA retweeted
Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies to contribute more abroad, writes PhRMA’s Steve Ubl. trib.al/Liplsq1
PhRMA retweeted
Aluminum based adjuvants and thimerosal are the two ingredients often questioned in conversations about #vaccines but the evidence supports their safety. Here are 4 things to know about vaccine ingredients: phrma.org/blog/what-to-know-… phrma.org/blog/what-to-know-…
PhRMA retweeted
The #340B program was meant to help patients, not pad hospital profits. But that's exactly what's happening in Ohio and across the country. New reporting adds to growing evidence that nonprofit hospitals exploit 340B markups while vulnerable patients see no benefit. Congress must act now on #340BReform. ohiocapitaljournal.com/2025/…
PhRMA retweeted
@jocelynulrich brings a rare blend of policy expertise and real-world insight to the table. As Vice President of Innovation Policy at @PhRMA, she translates complex industry dynamics into actionable ideas that protect both innovation and the patients we serve. Her perspective is essential for anyone who wants to understand how life-saving breakthroughs can coexist with a functioning, affordable healthcare system.
Cutting-edge therapies, from gene cures to cancer treatments, are transforming outcomes every day. But Jocelyn highlights a hidden crisis: middlemen capturing half of every rebate dollar, leaving patients to manage skyrocketing out-of-pocket costs. When the very people who need these medicines are priced out of reach, we undermine individual health and erode trust in the system.
Jocelyn makes the case that we can and must realign incentives so patients feel the full benefit of our innovations, not just the bill. By protecting patients at the pharmacy counter, we preserve hope and ensure that remarkable scientific advances do not become empty promises.
Listen to our full conversation with Jocelyn Ulrich on the Vital Health Podcast: omny.fm/shows/vital-health-p…
#Biotech #Pharma #Innovation #DrugDevelopment #IRA #PBM #HealthPolicy #Tarrif @DuaneSchulthess